Actively Recruiting
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
Led by University of Manitoba · Updated on 2026-02-03
1000
Participants Needed
1
Research Sites
452 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
CONDITIONS
Official Title
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.
You will not qualify if you...
- If informed consent cannot be obtained from the patient or their substitute decision maker.
- Known allergy to liquid embolic agent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Health Sciences centre
Winnipeg MB, Manitoba, Canada, R3A 1R9
Actively Recruiting
Research Team
J
Jai Shankar, MD
CONTACT
S
Susan Alcock, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here